DCVMN International, Route de Crassier 7, 1262 Eysins-Nyon, Switzerland.
Gracious International, 28 Jiafeng Road, Shanghai 200131, China.
Vaccine. 2020 Jul 22;38(34):5418-5423. doi: 10.1016/j.vaccine.2020.06.022. Epub 2020 Jun 11.
The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.
世界卫生组织宣布 COVID-19 疾病为大流行疾病，需要快速应对。通过在线搜索、与网络成员的直接沟通和内部调查，评估了发展中国家疫苗制造商网络成员在 COVID-19 疫苗研发方面的参与情况及其在疫苗生产、灌装和分销方面的能力。目前，有 19 个网络成员参与了 COVID-19 疫苗的研发，使用了六种主要的技术平台。此外，内部调查显示，2018-19 年，37 个成员共同供应的疫苗数量约为每年 35 亿剂。近三分之一的疫苗已获得世界卫生组织预认证的网络成员符合国际疫苗分发法规和机制。利用现有的生产、灌装和分销能力，可以支持 COVID-19 疫苗的高效推出，同时确保现有疫苗的供应安全，以维持正在进行的免疫规划。
